TISIDB

Summary
Symbol	SLC9A2
Name	solute carrier family 9, subfamily A (NHE2, cation proton antiporter 2), member 2
Aliases	NHE2; solute carrier family 9 (sodium/hydrogen exchanger), isoform 2; solute carrier family 9 (sodium/hydrog ......
Chromosomal Location	2q11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Membrane; Multi-pass membrane protein.
Domain	PF00999 Sodium/hydrogen exchanger family PF16644 Regulatory region of Na+/H+ exchanger NHE binds to calmodulin
Function	Involved in pH regulation to eliminate acids generated by active metabolism or to counter adverse environmental conditions. Major proton extruding system driven by the inward sodium ion chemical gradient. Seems to play an important role in colonic sodium absorption.

> Gene Ontology [ TOP ]
Biological Process	GO:0006813 potassium ion transport GO:0006814 sodium ion transport GO:0006818 hydrogen transport GO:0006885 regulation of pH GO:0015672 monovalent inorganic cation transport GO:0015992 proton transport GO:0030004 cellular monovalent inorganic cation homeostasis GO:0030641 regulation of cellular pH GO:0035725 sodium ion transmembrane transport GO:0051453 regulation of intracellular pH GO:0055067 monovalent inorganic cation homeostasis GO:0071804 cellular potassium ion transport GO:0071805 potassium ion transmembrane transport GO:0097369 sodium ion import GO:0098657 import into cell GO:0098659 inorganic cation import into cell GO:0098719 sodium ion import across plasma membrane GO:0098739 import across plasma membrane GO:0099587 inorganic ion import into cell GO:1902600 hydrogen ion transmembrane transport GO:1990118 sodium ion import into cell
Molecular Function	GO:0005451 monovalent cation:proton antiporter activity GO:0015077 monovalent inorganic cation transmembrane transporter activity GO:0015078 hydrogen ion transmembrane transporter activity GO:0015079 potassium ion transmembrane transporter activity GO:0015081 sodium ion transmembrane transporter activity GO:0015291 secondary active transmembrane transporter activity GO:0015297 antiporter activity GO:0015298 solute:cation antiporter activity GO:0015299 solute:proton antiporter activity GO:0015385 sodium:proton antiporter activity GO:0015386 potassium:proton antiporter activity GO:0015491 cation:cation antiporter activity GO:0022804 active transmembrane transporter activity GO:0022821 potassium ion antiporter activity GO:0046873 metal ion transmembrane transporter activity GO:0099516 ion antiporter activity
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-425407: SLC-mediated transmembrane transport R-HSA-425986: Sodium/Proton exchangers R-HSA-382551: Transmembrane transport of small molecules R-HSA-425393: Transport of inorganic cations/anions and amino acids/oligopeptides

Summary
Symbol	SLC9A2
Name	solute carrier family 9, subfamily A (NHE2, cation proton antiporter 2), member 2
Aliases	NHE2; solute carrier family 9 (sodium/hydrogen exchanger), isoform 2; solute carrier family 9 (sodium/hydrog ......
Chromosomal Location	2q11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between SLC9A2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	SLC9A2
Name	solute carrier family 9, subfamily A (NHE2, cation proton antiporter 2), member 2
Aliases	NHE2; solute carrier family 9 (sodium/hydrogen exchanger), isoform 2; solute carrier family 9 (sodium/hydrog ......
Chromosomal Location	2q11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of SLC9A2 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	SLC9A2
Name	solute carrier family 9, subfamily A (NHE2, cation proton antiporter 2), member 2
Aliases	NHE2; solute carrier family 9 (sodium/hydrogen exchanger), isoform 2; solute carrier family 9 (sodium/hydrog ......
Chromosomal Location	2q11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of SLC9A2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.255	0.421
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.017	0.978
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.447	0.42
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.077	0.893
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.236	0.879
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.126	0.946
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.423	0.613
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	1.862	0.217
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-1.199	0.454
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.109	0.816
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.23	0.708
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.695	0.0366

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of SLC9A2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	11.1	9.6	1.5	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	7.1	-7.1	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	11.1	10.2	0.9	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	14.3	17.6	-3.3	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	16.7	-16.7	0.429
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	23.1	18.2	4.9	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	13.2	14.8	-1.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	9.1	7.7	1.4	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	18.8	21.4	-2.6	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	SLC9A2
Name	solute carrier family 9, subfamily A (NHE2, cation proton antiporter 2), member 2
Aliases	NHE2; solute carrier family 9 (sodium/hydrogen exchanger), isoform 2; solute carrier family 9 (sodium/hydrog ......
Chromosomal Location	2q11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SLC9A2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	SLC9A2
Name	solute carrier family 9, subfamily A (NHE2, cation proton antiporter 2), member 2
Aliases	NHE2; solute carrier family 9 (sodium/hydrogen exchanger), isoform 2; solute carrier family 9 (sodium/hydrog ......
Chromosomal Location	2q11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SLC9A2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SLC9A2. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	SLC9A2
Name	solute carrier family 9, subfamily A (NHE2, cation proton antiporter 2), member 2
Aliases	NHE2; solute carrier family 9 (sodium/hydrogen exchanger), isoform 2; solute carrier family 9 (sodium/hydrog ......
Chromosomal Location	2q11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SLC9A2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	SLC9A2
Name	solute carrier family 9, subfamily A (NHE2, cation proton antiporter 2), member 2
Aliases	NHE2; solute carrier family 9 (sodium/hydrogen exchanger), isoform 2; solute carrier family 9 (sodium/hydrog ......
Chromosomal Location	2q11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of SLC9A2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	SLC9A2
Name	solute carrier family 9, subfamily A (NHE2, cation proton antiporter 2), member 2
Aliases	NHE2; solute carrier family 9 (sodium/hydrogen exchanger), isoform 2; solute carrier family 9 (sodium/hydrog ......
Chromosomal Location	2q11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between SLC9A2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	SLC9A2
Name	solute carrier family 9, subfamily A (NHE2, cation proton antiporter 2), member 2
Aliases	NHE2; solute carrier family 9 (sodium/hydrogen exchanger), isoform 2; solute carrier family 9 (sodium/hydrog ......
Chromosomal Location	2q11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting SLC9A2 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse SLC9A2